We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
George
Hanna
g.hanna@imperial.ac.uk
VAPOR
Trial Manager
vapor@imperial.ac.uk
Malignant neoplasms of digestive organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Pancreatic cancer has extremely poor survival in the UK, with just 7.3% of patients surviving 5 years after diagnosis. This is largely due to a failure of early-detection, with 45% of pancreatic cancer cases presenting as an emergency. Diagnosing pancreatic cancer at an earlier stage remains a challenge as the signs and symptoms of early pancreatic cancer are often non-specific, and late diagnosis is therefore a common feature of pancreatic cancer, with 47% of patients presenting with Stage 4 disease.
This study aims to improve earlier detection of pancreatic cancer by developing a non-invasive breath test for patients living with non-specific symptoms of pancreatic cancer. The breath test detects small molecules called volatile organic compounds (VOCs) that we believe are released by pancreatic cancers. For patients with non-specific symptoms, this test would help GPs to identify those patients that may indeed have an underlying pancreatic cancer, who would benefit from referral for specialised pancreatic cancer tests.
The study will be a prospective multi-centre observational study, to find out which VOCs can be used as markers of pancreatic cancer, by finding out what volatile compounds are made in different groups of patients. We will test patients with known pancreatic cancer, benign pancreatic conditions (new-onset diabetes and chronic pancreatitis) and healthy patients.
In addition to this, we aim to establish a comprehensive bioresource of matched samples from patients with pancreatic cancer as well as controls. Biosamples including breath, saliva, blood, urine, pancreatic tissue and duodenal contents will be collected and analysed to further investigate the pathways of VOC production in pancreatic cancer. The results of these studies will be used to refine our breath test.
We hope that this will allow us to diagnose pancreatic cancer earlier, leading to more treatment choices for patients and improved survival from pancreatic cancer.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Clinical Laboratory Study;
You can take part if:
You may not be able to take part if:
Exclusion criteria (BIORESOURCE and VAPOR 1): - Patients who have already received chemotherapy, radiotherapy or surgery for their PDAC - Patients with active infection, receiving immunosuppressive medications or antibiotics within the preceding eight weeks - History of another cancer within the previous five years - Previous upper gastrointestinal surgery - Patients who are unable to provide a breath sample - Pregnant women - Patients unable to provide informed written consent
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by Imperial College of Science, Technology and Medicine and funded by PANCREATIC CANCER UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 53691
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
